HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

monoclonal antibody 6B1 IgG4 (Lerdelimumab)

human anti-TGF beta 2 antibody for preventing post-operative scarring in patients undergoing surgery for glaucoma (trabulectomy); also has potential for the treatment of fibrosis, cataract, retinopathy and connective tissue disease
Also Known As:
Lerdelimumab; CAT-152; MAb 6B1 IgG4
Networked: 7 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Cordeiro, M Francesca: 3 articles (08/2003 - 03/2002)
2. Khaw, Peng T: 2 articles (08/2003 - 03/2002)
3. Grehn, Franz: 1 article (10/2007)
4. Holló, Gábor: 1 article (10/2007)
5. Wilson, Rosamund: 1 article (10/2007)
6. Khaw, Peng: 1 article (10/2007)
7. Vogel, Roger: 1 article (10/2007)
8. Smith, Zaid: 1 article (10/2007)
9. Overton, Barry: 1 article (10/2007)
10. CAT-152 0102 Trabeculectomy Study Group: 1 article (10/2007)

Related Diseases

1. Cicatrix (Scar)
2. Blister (Bulla)
3. Glaucoma
4. Capsule Opacification
5. Wounds and Injuries (Trauma)

Related Drugs and Biologics

1. Fluorouracil (Carac)
2. monoclonal antibody 6B1 IgG4 (Lerdelimumab)
3. Transforming Growth Factor beta2
4. Transforming Growth Factor beta (TGF-beta)
5. Antimetabolites
6. Antibodies

Related Therapies and Procedures

1. Filtering Surgery
2. Injections
3. Trabeculectomy (Trabeculoplasty)